Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to announce its fiscal first-quarter earnings next month, and analysts project a high single-digit decline in losses.

Barchart

What to know about OpenAI's new model for life sciences research GPT-Rosalind

The GPT-Rosalind model is designed to accelerate biological research and drug discovery.

Euronews

Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international contracts may surprise bears in 2026.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

America is handing its mRNA lead to China—and RFK Jr. is to blame

Political interference is driving biotech investment overseas, and U.S. patients and workers will pay the price.

Fortune

The S&P 500's 3 Best-Performing Stocks So Far in 2026

Despite a broad market selloff, SNDK, TPL, and MRNA stand out as the S&P 500's 3 best-performing stocks in 2026, each operating in a different sector.

MarketBeat

US vaccine panel retreats from mRNA Covid review ahead of midterms

Advisers to RFK Jr drop the plan to end federal guidance amid Republican worries about the political impact

The Guardian - US

Is Moderna Stock Outperforming the Dow?

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

FDA to offer bonus payments to staffers who complete speedy drug reviews

The head of the Food and Drug Administration plans to start offering bonus payments to agency drug reviewers who complete their work ahead of the schedule

The Independent UK

FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from public health experts.

The Conversation

FDA will drop two-study requirement for new drug approvals, aiming to speed access

The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals

The Independent UK

Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here?

Moderna shares extend gains as FDA reverses its refusal-to-file decision on the firm’s influenza vaccine. Here’s why MRNA shares still aren’t attractive to own in 2026.

Barchart

FDA reverses course and will review Moderna’s mRNA-based flu vaccine

US drug regulator originally refused to consider application, fueling critics’ concern about alleged ‘anti-vaccine agenda’

The Guardian - US

Moderna says the FDA will consider its new flu shot after resolving a public dispute

Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults after all

The Independent UK

FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’

Experts say ‘they’re just coming up with reasons’ as agency says application lacked ‘adequate and well controlled’ trial

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Reason

Clinical Trials Show Moderna's New mRNA Flu Vaccine Is Safe and Effective. FDA Won't Even Consider It.

An overzealous government agency suppresses medical innovation yet again.

The Conversation

FDA rejects Moderna’s mRNA flu vaccine application - for reasons with no basis in the law

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine.

The Independent UK

First mRNA vaccine to be produced in UK approved by regulators

The Moderna Innovation and Technology Centre will make millions of cutting-edge mRNA vaccines

The Guardian - US

FDA declines to review Moderna application for new flu vaccine

Moderna requests meeting to discuss refusal as decision could have implications for all new and updated vaccines

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FDA declines to review Moderna’s new flu vaccine

This decision signals heightened scrutiny of vaccines by the FDA under Health Secretary Robert F. Kennedy Jr.

Barchart

Can This Former Pandemic Star Make a Stunning Comeback?

Moderna is betting its mRNA pipeline can power the next growth cycle.

Reason

How To Speed Up the Search for Cures Through a Change in Probability Theory

It seems likely the FDA would do well to accept more Bayesian reasoning in medical research.

Barchart

Are Wall Street Analysts Bullish on Moderna Stock?

While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

MarketBeat

3 ETFs Catapulting Beyond the S&P to Start the Year

Three ETFs with year-to-date performance of 30% or better include a fund focused on drone technology, one targeting nickel miners, and a covered call play.

Euronews

Promising vaccine for aggressive melanoma could unlock the body’s potential to fight cancer

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

MarketBeat

Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?

COVID-19 vaccine stock Moderna just got its biggest lift in recent memory, moving up 17%. Can MRNA stage a broader recovery, down +90% from its all-time high?

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

the Food and Drug Administration

219 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.